HEALTH● LOWAug 13 · Aug 13, 2026, 6:59 PM
Cellectar targets mid-2027 accelerated approval NDA for iopofosine in WM, backed by up to $140M financing
Seeking Alpha Tech
Cellectar aims for accelerated FDA approval by mid-2027 for iopofosine in WM, supported by up to $140 million in financing. This indicates a key strategic move for the company and its drug development.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH8m agoProud Kakinada is at the heart of India’s return to making Penicillin, says Andhra HRD Minister Nara LokeshThe HinduHEALTH12m agoKeralam to adopt calendar-based infectious disease prevention strategyThe HinduHEALTH23m agoItaly first in Europe to establish national plan against fentanyl says MeloniANSA [en]HEALTH26m agoMalaria: Nigeria’s prevalence drops to 15.2%, FG targets 50% reduction by 2030Vanguard Nigeria